Skip to main content
NC3Rs | 20 Years: Pioneering Better Science

Our funders

NC3Rs funders 

In 2022/23 the NC3Rs had a budget of £11.19M. The NC3Rs receives core funding from the MRC and BBSRC, which are part of UK Research and Innovation (UKRI). Core funding is reviewed every five years. In financial year 2022/23 the core funding was £10.2M. In addition to this, the NC3Rs received funding for specific programmes and posts and co-funding for awards from other research funders. In 2022/23, this included funding from the following organisations: 

  • Association of the British Pharmaceutical Industry (ABPI)* 
  • British Heart Foundation 
  • Cancer Research UK 
  • Engineering and Physical Sciences Research Council
  • GSK 
  • Shell 
  • Syngenta 
  • Corteva Agriscience 
  • Unilever
  • Wellcome 
  • Bill and Melinda Gates Foundation 
  • The Francis Crick Institute 
  • Great Western 4 Alliance (University of Bath, University of Bristol, Cardiff University and University of Exeter) 
  • King’s College London 
  • London School of Hygiene and Tropical Medicine 
  • Royal Veterinary College 
  • University College London 
  • University of Birmingham 
  • University of Leicester 
  • University of Nottingham 
  • University of Oxford 

* in accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance Laboratories, Charles River Laboratories and UCB Pharma. 

Budget 

Table 1 shows the NC3Rs income and expenditure for the financial year 2022/23. Expenditure is divided across three areas – research and innovation awards made to universities and SMEs, support for early career researchers (e.g. funding for PhD studentships) and programmes led by NC3Rs scientific staff. 

Table 1: Income and expenditure

Type

Amount

£M

Income -
Core 10.2
Non-core 0.99
Expenditure -
Research and innovation awards 6.37
Early career awards 1.51
Science programmes led by NC3Rs staff 3.23